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Abstract
Background First reported in 1955, Cronkhite–Canada
syndrome (CCS), a rare syndrome characterized by ecto-
dermal abnormalities and inflammatory changes of the
gastrointestinal tract mucosa, has been associated with a
poor prognosis and life-threatening malignant complica-
tions. In a large population survey, we endeavored to
characterize the course and treatment outcome of CCS
through clinical and endoscopic assessment, and to explore
its optimal treatment and surveillance strategy.
Methods A retrospective analysis of 210 patients with
CCS was conducted via a questionnaire-based nationwide
survey of 983 teaching hospitals located throughout Japan.
We assessed clinical features, endoscopic findings, treat-
ments used, and short- and long-term outcomes.
Results The average age at diagnosis was 63.5 years. In
all cases, upper or lower gastrointestinal tract polyposis
was confirmed, accompanied by characteristic ectodermal
abnormalities. Of the treatments used, oral corticosteroids
(30–49 mg/day) were the most effective treatment for
active disease, with adjunctive nutritional support consid-
ered beneficial. With corticosteroid treatment, abdominal
symptoms were relieved within a few months, whereas
polyp regression often required more than 6 months.
Maintenance of endoscopic remission with or without
steroids for 3 years significantly lowered the development
of CCS-related cancer, compared with relapsers or nonre-
sponders, underscoring the importance of sustained endo-
scopic remission for cancer prevention.
Conclusions The prognosis of CCS has greatly improved
through the use of improved medical treatment. Although
CCS continues to be relentlessly progressive, carrying a
high cancer risk, a sufficient dose and duration of corti-
costeroid therapy accompanied by nutritional support and
periodic endoscopic surveillance appears to improve its
natural history.
Keywords Acquired gastrointestinal polyposis
syndrome  Malnutrition  Gastric cancer  Colon cancer
Introduction
Cronkhite–Canada syndrome (CCS) is an uncommon gas-
trointestinal polyposis syndrome characterized by derma-
tologic manifestations associated with chronic diarrhea,
malnutrition, and enteric protein wasting due to chronic
inflammatory changes of the intestinal mucosa [1–5]. The
risk of colon cancer in CCS patients may be elevated owing
to difficulties in detecting premalignant adenomas in the
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face of multiple inflammatory pseudopolyps. Since it was
first reported by Cronkhite and Canada [6], more than 400
cases of CCS have been reported worldwide, with 75 %
reported from Japan [1, 3, 7–10]. Given the rarity of CCS,
current understanding is based on anecdotal reports and
small case series, [10, 11], with no published systematic
investigations based on endoscopic features. CCS is
sometimes difficult to diagnose for clinicians and pathol-
ogists alike, owing to the considerable overlap of histologic
and clinical features shared among CCS-related, juvenile,
and inflammatory polyps [3, 12–14]. Its clinical course is
characterized by progressive disease with occasional
spontaneous remissions and frequent relapses [15–18], with
rare progression to malignancy [1, 19, 20]. Concomitant
cancers occurring in the gastrointestinal tract have been
reported, although no systemic investigation of the cancer
risk and prognosis has been published since the 1980s [11,
19–23]. The mortality of CCS can be up to 50 % if it is
untreated or if treatment is delayed or inadequate [11].
Nevertheless, no treatment in use to date is based on sys-
tematically acquired data based on the study of a large
population of CCS patients.
Current CCS treatments used individually or in combi-
nation include steroids [1, 11, 17, 18, 24], nutritional
therapy [25], 5-aminosalicylate acid [26], histamine H2
receptor antagonists [27], anti-tumor necrosis factor a
(TNF-a) agents [28], immunomodulators [28], and eradi-
cation of Helicobacter pylori [29]. Steroids are considered
the mainstay of medical treatment, although the recom-
mended dose and duration of their use have varied widely
in the literature, with no current ‘‘gold standard’’ [11, 17,
18, 30]. Since symptom relapse is common during a steroid
taper, a steroid-sparing strategy is needed.
The risk of gastrointestinal cancer may warrant
aggressive screening of CCS patients. Since it is nearly
impossible to endoscopically detect malignant polyps or
concurrent adenocarcinoma given the myriad of inflam-
matory-type polyps in CCS patients, an evidence-based
surveillance program is needed. Therefore the aims of this
study were (1) to elucidate the endoscopic characteristics,
long-term prognosis, and cancer risk of CCS, and (2) to
identify whether corticosteroid therapy can improve pri-
mary and long-term outcomes, and if so, what dose and
duration are optimal, and (3) to suggest the ideal endo-
scopic surveillance schedule for CCS, by the use of data
from a nationwide survey in Japan.
Materials and methods
A questionnaire-based nationwide survey of CCS was con-
ducted in 983 Japanese teaching hospitals specializing in
gastroenterology. To obtain the most accurate endoscopic
information, clinical and endoscopic data were collected
from hospitals registered with the Japanese Society of Gas-
troenterology. The preliminary survey asked: ‘‘Has your
institute treated patients with Cronkhite–Canada syndrome?
If yes, how many?’’ Responses were received from 591 of
983 facilities (60.1 %), revealing 213 patients with CCS
were treated in 140 facilities between 2000 and 2013. A
detailed survey was sent to these facilities, with information
obtained from 139 facilities describing 210 patients. The
detailed survey consisted of 133 question items organized
into 11 sections requesting detailed clinical features,
including endoscopic findings, polyp pathology, response to
treatment, and prognosis, with an emphasis on the risk of
developing gastrointestinal cancer.
Demographic and explicit clinical, laboratory, and
endoscopic data were collected at the time of diagnosis.
Clinical symptoms such as diarrhea and ectodermal
abnormalities, and laboratory tests including testing for
protein-losing enteropathy, autoimmunity, or H. pylori
infection were documented. Endoscopic features included
the distribution pattern and size of polyps, and the mucosal
appearance of polyps, noting if they appear to be friable,
edematous, or engorged [31]. Histological features such as
gland dilation or crypt distortion such as branching or
withering and the degree of inflammatory cell infiltration
were noted.
Treatment outcome was evaluated in two stages. Early
outcome was evaluated 6–12 months after the start of
treatment or initial diagnosis. Treatment outcome was
assessed primarily on the basis of endoscopic improvement
of mucosal findings. Early outcomes were classified into
‘‘good response’’ and ‘‘no-response’’ groups. ‘‘Good early
response’’ was defined as partial regression of polyposis
with mild friability or decreased erythema. ‘‘Endoscopic
remission’’ was defined as the absence of polyposis with
normal appearance of mucosa, accompanied by a clinical
response. ‘‘No early response’’ was defined as no signifi-
cant endoscopic improvement irrespective of clinical
response. ‘‘Clinical response’’ was defined as regression of
clinical symptoms accompanied by normalization of the
serum albumin concentrations (clinical remission).
The subsequent outcome was evaluated over a 3-year
period after initial induction treatment with corticosteroids
had started, and patients were classified into ‘‘long-term
response‘‘ and ‘‘no long-term response’’ groups. ‘‘Long-
term response’’ includes the maintenance of complete
remission and partial remission. ‘‘Complete remission’’
was defined as endoscopic and clinical remission without
ongoing medical treatment. ‘‘Partial remission’’ was
defined as near endoscopic remission accompanied by
clinical remission while the patient was receiving stable
corticosteroid therapy at less than 10 mg/day for more than
1 year. ‘‘No long-term response’’ includes episodically
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active disease and clinically chronic active disease without
a long-lasting endoscopic remission or improvement. In
episodic active clinical disease, frequent use of corticos-
teroids was necessary to prevent endoscopic relapse. In
chronic active disease, sustained endoscopic improvement
was not achieved, even with long-term, high-dose corti-
costeroid therapy. The v2 test was used to compare two
discrete variables, whereas the nonparametric test was used
to compare discrete and a continuous variable. Significance
was taken as 5 %. The study was approved by the Ethics
Committee of the National Defense Medical College.
Results
Of 210 patients with CCS, 136 were men and 74 were
women, yielding a male-to-female ratio of 1.84:1. The
mean age of onset of symptomatic disease was 63.5
(31–86) years. The observation period was 5.93 ± 4.85
(0.5–28) years. All patients were Japanese, except for two
non-Japanese Asian women. There was no evidence of
polyposis in any blood relatives. Of the 210 patients, 33
(15.7 %) had died at the time of the survey. Of the 33
deaths, ten were disease-related (three patients died of
gastric cancer, three patients died of colon cancer, and four
patients died of sepsis caused by colitis and pancreatitis),
whereas the other 23 patients died of illness presumed to be
unrelated to the primary disease (e.g., lung cancer, cerebral
stroke, and cardiac disease).
Two hundred three patients underwent esophagogastro-
duodenal endoscopy and/or ileocolonoscopy. The jejunal
and ileal mucosae were visualized by contrast radiography,
enteroscopy, and capsule endoscopy in 59, 29, and 37
patients, respectively. Table S1 gives the location and
Fig. 1 shows the endoscopic appearance of gastrointestinal
polyps. In this survey, in contrast to prior reports [10, 11],
the esophagus was involved in 26 cases (12.3 %). Most of
the esophageal biopsies revealed nonspecific inflammation,
and some showed squamous papilloma of the esophagus.
Compared with the stomach and colon, the jejunum and
ileum were not as severely involved, mostly populated with
sparsely distributed smaller polyps (less than 10 mm),
which are likely difficult to detect among the markedly
inflamed mucosa. Gastric and colonic polyps were mostly
sessile (2–40 mm) with engorged mucosa and rare punctate
hemorrhages. Gastric polyps were smaller and more con-
fluent than their colonic counterparts (Fig. S1). The useful
distinguishing feature of juvenile polyps is abnormal-ap-
pearing edematous and reddish mucosa between polyps
[12, 18], which was observed in the stomach and colon in
74 and 57.6 % of cases, respectively.
Analysis of the histological results of 189 stomach
biopsies and 197 colon biopsies revealed that nearly half of
the gastric polyps (52.4 %; 99 of 189) and 57.9 % of
colonic polyps (114 of 197) displayed common features
typical of CCS polyps such as focal dilated cystic glands,
some filled with proteinaceous fluid or inspissated mucus,
whereas the others displayed hyperplastic, inflammatory, or
adenomatous features. Prominent infiltration of eosino-
phils, lymphocytes, and neutrophils was present in one
third. Typically, the polyp and interpolyp area was ede-
matous, with congestion and chronic inflammation of the
lamina propria and submucosa, even though endoscopi-
cally the mucosa appeared normal (data not shown).
As shown in Table 1, 60 separate gastrointestinal tract
carcinomas (19 gastric cancers and 41 colon cancers) were
diagnosed either at initial presentation or during the
observation period, with adenomas diagnose in 72 patients.
Cancer or adenoma was limited to the stomach or colon,
with no dysplastic lesions located in the esophagus or in the
small intestine. In the colon, 36 CCS patients (17.1 %)
adenomatous changes were diagnosed at the first endo-
scopy. No preferential localization of colon cancer was
present in CCS patients, with advanced colon cancers
evenly distributed throughout the large intestine (six
ascending colon, one transverse colon, five sigmoid colon,
five rectum, two multiple sites).
The common symptoms or prevalent physical findings,
and laboratory data are shown in Table 2. Chronic diarrhea
was reported in 78.3 % of patients. Ectodermal changes
were present in more than 70 % of patients, with 91.3 %
having the single finding of alopecia, onychodystrophy, or
skin hyperpigmentation (Fig. S1). Hyperpigmentation was
described as lentigo-like to light to dark brownish macules,
distributed on the palms and soles, upper extremities, face,
and chest. Although rare, one of the important CCS com-
plications is intestinal bleeding. Of 20 patients with gas-
trointestinal bleeding, two bled massively; one from an
eroded gastric polyp, and the other from an advanced
gastric cancer. Another major complication is intussus-
ception: ten patients developed colo-colic intussusception
due to a polyp serving as the intussuscipiens, with three
requiring surgical therapy.
As shown in Table 2, a significant decrease in total protein
and albumin was initially present, which improved after
initial treatment. Fecal a1-antitrypsin clearance or
99mTc-
albumin scintigraphy revealed a high prevalence of gas-
trointestinal tract protein loss. Of 113 patients screened for
H. pylori, 61 (54.0 %) were positive, with successful eradi-
cation in 15, with endoscopic remission or response attained
in 8 (53.3 %), although one patient developed gastric cancer
after successful eradication. Of the 19 CCS patients with
gastric cancer (not included in the H. pylori screened sub-
jects), two were negative forH. pylori, and six were positive.
Figure 2 depicts a flow diagram for the treatment and
clinical course of the 210 patients. Nine patients did not
J Gastroenterol (2016) 51:327–336 329
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Fig. 1 Endoscopic findings of gastrointestinal polyps in patients with
Cronkhite–Canada syndrome. A distribution and size of polyps. The
outer circle shows the distribution pattern, and the inner circle shows
the predominant size of the polyps. Data are expressed as the
percentage of the total number of patients. The dominant types in the
small intestine were sparsely distributed smaller polyps. The polyps in
the stomach were more confluent than those in the colon (81.9 % vs
54.5 %, p\ 0.01), and smaller (in the stomach 18.1 % were larger
than 15 mm, 51.4 % were 5–10 mm, and 30.5 % were smaller than
5 mm, and in the colon 30.4 % were larger than 15 mm, 44.6 % were
5–10 mm, and 25 % were smaller than 5 mm; p\ 0.05). B endo-
scopic appearance of polyps. Appearance was classified into four
categories (edematous, engorged, with erosion, or with hemorrhage)
according to the most dominant appearance. C the endoscopic
appearance in the mucosa between the polyps was classified as
normal or abnormal. Abnormal usually indicates edematous or
reddish coarser mucosa than normal (74 % in the stomach and
57.6 % in the colon, p\ 0.01)
Table 1 Number of Cronkhite–Canada syndrome patients associated with gastric and colorectal cancer or adenoma
Cancer Adenoma
Gastric Colon Gastroduodenal Colon
Early Advanced Total Early Advanced Total
Associated patients
At initial presentation 7 (3.3 %) 6 (2.9 %) 13 (6.2 %) 11 (5.3 %) 15 (7.1 %) 26 (12.4 %) 4 (1.9 %) 36 (17.1 %)
During observation 2 (1.0 %) 4 (1.9 %) 6 (2.9 %) 10 (4.8 %) 5 (2.4 %) 15 (7.1 %) 3 (1.4 %) 29 (13.8 %)
Observation period (years) 10 ± 7.1 11.7 ± 7.0 11.0 ± 6.2 8.8 ± 4.6 10.2 ± 8.2 9.2 ± 5.9 7.7 ± 7.4 6.4 ± 4.8
Total 9 (4.3 %) 10 (4.8 %) 19 (9.1 %) 21 (10.1 %) 20 (9.5 %) 41 (19.5 %) 7 (3.3 %) 65 (31.0 %)
Therapeutic outcome
Endoscopic resection 6 16 3 35
Surgery 9 19 3 2
Death 3 3 3 1
Total of 210 patients. Adenomas bearing carcinomatous foci (n = 7), and adenomas that evolved into carcinoma (n = 28) were regarded as
cancer. Three patients had both gastric and colon cancers, which were counted individually. All early colon cancers were found close to the
adenoma.
330 J Gastroenterol (2016) 51:327–336
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receive any intervention. Among them, three experienced
spontaneous complete symptomatic remission without
medication or nutritional therapy, sustained for more than
5 years. Among 201 treated patients, 178 received corti-
costeroid treatment, with the others were treated either with
nutritional therapy or with surgical or endoscopic treatment
alone. Treatment outcomes at 1 year were available for 173
patients: in the 23 patients who did not receive steroids, 21
were classified as having no early response, whereas a good
early response was reported by 80.0 % (120/150) of the
group in whom corticosteroid therapy was initiated and
continued for 1 year. Among 30 no early response cases,
seven patients failed to respond who had progressive dis-
ease requiring intensive therapy, with 86 % receiving
intensive therapy, such as calcineurin inhibitors, octreotide,
and anti-TNF-a agents, attaining a good early response.
Among those who were treated with corticosteroids for
1 year, the subsequent outcome was evaluated in 108
patients over the following 3 years.
Nutritional therapy, including total parenteral nutrition
and a defined-formula diet, frequently accompanied steroid
therapy. Among 150 patients receiving corticosteroid
treatment for 1 year, concurrent nutritional therapy was
used in 68 (45.3 %), with 94 patients receiving nutritional
therapy, including total parenteral nutrition and a defined-
formula diet. Yet, no significant difference in the good
early response group was noted between groups receiving
(90 %; 60 of 68) or not receiving (81 %; 61 of 75) nutri-
tional therapy, suggesting no apparent additional beneficial
effect of the nutritional therapy used.
Figure 3 shows the time course of clinical features by
cumulative clinical remission rate after the induction of
medical treatment. Remission of diarrhea occurred over
51 days, followed by reversal of dysgeusia (84 days) and
ectodermal changes (97 ± 11.2 days). Decrease in the size
and number of polyps was slower, averaging 248 days for
gastric polyps and 238 days for colonic polyps.
Steroid therapy regimens differed among centers.
Although dose escalation improved therapeutic outcomes,
it was accompanied by severe side effects such as sepsis
and thrombosis for dosages exceeding 60 mg/day.
Table S2 depicts the 1-year endoscopic response (good
Table 2 Clinical variables: symptoms and laboratory findings in Cronkhite–Canada syndrome
Symptoms At initial diagnosis (%) Overall frequency (%)
Diarrhea 70.0 78.3
Dysgeusia 64.8 81.3
Alopecia 49.0 80.0
Onychodystrophy 64.4 89.0
Hyperpigmentation 48.8 70.1
Bleeding 1.44 9.6
Intussusception 0.96 4.8
Laboratory findings At initial diagnosis After initial treatment pb
Hemoglobin (g/dl) 13.0 ± 2.49 13.9 ± 2.02 0.68
Total protein (g/dl) 5.35 ± 0.94 6.37 ± 0.88 \0.01
Albumin (g/dl) 2.96 ± 0.74 3.83 ± 0.63 \0.01
Total cholesterol (mg/dl) 147.2 ± 34.9 196.9 ± 42.0 \0.01
C-reactive protein (mg/dl) 0.94 ± 2.53 0.16 ± 0.38 \0.01
Laboratory findings At initial diagnosis Normal range
IgG (n = 91) 812.6 ± 296.2 mg/dl 680–1620 mg/dl
Positive ANA test result (n = 72) 27.7 %
Zinc (n = 65) 73.6 ± 21.7 lg/dl 80–160 lg/dl
Elevated a1-antitrypsin clearance (n = 30) 93.3 % \20 ml/day
Positive 99mTc-albumin scintigraphy finding (n = 56) 75 %
Helicobacter pylori positivity (n = 113)a 54.0 %
Total of 210 patients.
ANA antinuclear antibodies
a Diagnostic testing for H. pylori was performed with one of or a combination of rapid urease testing, culture, histology, IgG antibodies to H.
pylori, or fecal antigen.
b Statistical comparison laboratory data between ‘‘at initial diagnosis‘‘ and ‘‘after initial treatment’’
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early response) stratified by initial dose. Since a greater
than 85 % response was observed with dosages exceeding
30 mg/day, dosing at 30–49 mg/day appears optimal.
The subsequent course of patients treated with corti-
costeroids is shown in Fig. 4. Among 108 CCS patients
who were initially treated with steroids and who were
regularly evaluated for more than 3 years, 61.1 % (66 of
108) had a long-term response, whereas 38.9 % (42 of 108)
had no long-term response. Of 66 patients who went into
endoscopic remission (long-term response) after comple-
tion of an initial trial of steroid therapy, 36 patients
(54.5 %) remained in endoscopic remission without further
steroid therapy during the observation period (complete
remission), and 30 patients (45.4 %) had sustained endo-
scopic remission with stable low-dose corticosteroid ther-
apy (less than 10 mg; partial remission). Of the 42 patients
who could not achieve sustained endoscopic remission (no
long-term response), 16 (38.0 %) experienced frequent
relapses after corticosteroid withdrawal (episodic active)
and 26 (61.9 %) relapsed during tapering or for them
steroid treatment could not be withdrawn (chronic active
disease).
The ultimate aim of treatment is to prevent the
development of CCS-related cancer. As shown in Fig. 4,
sustained endoscopic improvement correlated with a
significantly diminished risk of developing gastrointesti-
nal cancer and CCS-related death due to complications.
Among 66 patients with sustained endoscopic response
(long-term response), only one case of cancer emerged,
with no CSS-related death during the 3 years, whereas in
the no long-term response group, a significantly higher
incidence of cancer (17/42) and CSS-related death (7/42)
was observed (p\ 0.01).
After initial steroid treatment, immunomodulators or
anti-TNF-a agents may possibly reduce or eliminate ster-
oid use, preventing the recurrence of CCS-related polyps
[5]. Of the five patients receiving azathioprine, two did not
relapse during 2–11 years of monitoring, although three
developed cancer with relapse of polyposis. Two patients
who received a calcineurin inhibitor and one patient who
received an anti-TNF-a agent remained in remission for
3 years. Nevertheless, in this survey, therapy with his-
tamine H2 receptor antagonists or 5-aminosalicylate acid,
which were taken by 28 or 46 patients, respectively, did not
affect clinical or endoscopic outcomes or the risk of cancer
when it was combined with other medications (data not
shown).
Of 37 surgical operations performed in 36 patients,
seven were for gastric cancer, 19 were for colon cancer,
three were for gastroduodenal adenoma, one was for
severe enteric protein loss, four were for intussusception,
two were for gastric bleeding, and one was for gastric
gastrointestinal stromal tumor. No operative complica-
tions were reported. The mean duration of posttreatment
follow-up of the surviving patients was 5.1 (0–14) years.
Although symptomatic remission was attained in all
cases, remission could not be attributed to the resection,
since medical therapy, in particular steroid treatment,
more likely contributed to the improvement.
Fig. 2 Flow diagram of
treatment choice and clinical
course of patients with
Cronkhite–Canada syndrome
(CCS) *1 of 23 patients without
steroid treatment, eight patients
were treated with nutritional
therapy and 15 patients
underwent surgical/endoscopic
treatment alone. *2 among 30
patients who failed to respond to
corticosteroid treatment, seven
patients showing progressive
disease required intensive
therapy with calcineurin
inhibitors (n = 4), octreotide
(n = 1), anti-TNF-a agents
(n = 1), and colectomy (n = 1).
With the exception of one
patient treated with a
calcineurin inhibitor who failed
to respond, the others attained
endoscopic response
332 J Gastroenterol (2016) 51:327–336
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Discussion
We investigated the clinical characteristics, response to
medical treatment, and prognosis of 210 patients with CCS.
Contrary to earlier reports [10, 11], the prognosis of CCS has
greatly improved through advances in medical treatment,
although the course of CCS is relentlessly progressive,
accompanied by an elevated cancer risk. Corticosteroid
therapy, timely endoscopic evaluation, and the progress of
medical management appear to improve the natural history
of CCS. From our study, the diagnosis of CCS is confirmed
by combination of clinical signs such as ectodermal abnor-
malities with characteristic foregut and hindgut endoscopic
findings. Small bowel involvement, characterized as spar-
sely distributed small polyps, was difficult to detect radio-
logically. Histological diagnosis depends on the sample
location, with the highest yield obtained from biopsies of the
polyp and the adjacent mucosa. Since adenoma or early
cancer commonly exists in the background of severe
inflammation, it is difficult to endoscopically discriminate
malignant polyps or concurrent adenocarcinoma among the
numerous inflammatory CCS polyps.
Clinical manifestations followed a similar course in
most patients, initially diarrhea, followed by ectodermal
changes, which were at times attributed to malnutrition,
since ectodermal changes improved with nutritional
repletion. Lastly, inflammatory polyposis slowly regressed,
taking as long as 240 days, indicating that long-term
monitoring is required to assess treatment outcomes, even,
in most cases, after remission of clinical symptoms. We
thus strongly advocate continued endoscopic surveillance
even after clinical remission has been achieved.
Fig. 3 The cumulative clinical
remission rate over time and
mean time to remission.
Asterisk the mean time to
remission is significantly longer
compared with the mean time
for diarrhea (p\ 0.05 vs
diarrhea), dagger p\ 0.05
versus onychodystrophy, S.E.
standard error
Fig. 4 Three-year outcome of
steroid treatment in 108 patients
who attained a good response.
Of the 108 patients, 66 achieved
a long-term response (36
‘‘complete remission’’ and 30
‘‘partial remission’’), and 42 had
no long-term response (16
‘‘episodic active’’ and 26
‘‘chronic active’’). Among those
patients, the occurrence of
cancer (4 gastric cancer and 14
colon cancer) and Cronkhite–
Canada syndrome (CCS)-related
death (one death due to sepsis
caused by colitis, two deaths
due to gastric cancer, and four
deaths due to colon cancer) are
shown
J Gastroenterol (2016) 51:327–336 333
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Traditionally, steroid therapy and nutritional support are
the mainstays of medical treatment [1, 11, 17, 24]. We
confirmed that a 30–49-mg daily dose of orally adminis-
tered prednisolone was optimal for active CCS. A too-rapid
steroid dose reduction can be associated with early relapse,
suggesting that the prednisolone dose should be slowly
tapered only after endoscopic confirmation of regression of
polyposis. Poorer nutritional status at diagnosis may have
increased the time to attain endoscopic remission with
steroid therapy; therefore, those at higher risk from steroid
therapy such as the elderly and those with a history of
tuberculosis may benefit from nutritional support and
consequent shortening of the length of steroid regimens.
Steroid-sparing therapies such as cyclosporine A, octreo-
tide, and an anti-TNF-a agent, which showed promise in a
few cases, can be used in steroid-resistant cases in order to
induce or maintain clinical remission. Although azathio-
prine used with or without steroid maintenance therapy was
reported to be associated with sustained clinical remission
[1, 5, 32], we could not confirm this finding. Since
immunological dysregulation is one of the important fac-
tors hypothesized to be present in CCS [5, 14, 33–36], the
long-term use of immunoregulatory drugs or biologics may
be useful for active or refractory disease.
One of our major findings was that achievement of
sustained endoscopic remission was unambiguously asso-
ciated with decreased cancer risk. Formerly, it was reported
that total regression of polyps could not be attained even
after long-term sustained clinical remission, with ‘‘at-
rophic’’ polyps observed [37]. Although histological con-
firmation is difficult, endoscopic documentation of
regression of polyposis is likely to be an important primary
therapeutic end point.
The increased incidence of gastric and colorectal carci-
noma suggests the need for regular surveillance [17]. As
previously mentioned, detection of malignancy at initial
endoscopy is extremely difficult. Surveillance may be prac-
tical only after the diffuse inflammatory polyps have regressed
with steroid therapy, which then reveals the otherwise ‘‘bur-
ied’’ adenomas or cancer, even in patients with sustained
clinical remission. In four cases, advanced endoscopic imag-
ing techniques, such as narrow-band imaging, magnifying
endoscopy, and dye-based contrast-enhancement techniques,
were helpful in identifying concurrent premalignant or
malignant lesions that could be successfully resected, as pre-
viously reported (data not shown) [38, 39]. The surveillance
interval thereafter is empiric, but as a minimum annual
surveillance is recommended [1, 17], because in this survey
we observed endoscopic recurrence in several cases before
clinical recurrence approximately 1 year after discontinua-
tion of corticosteroid therapy.
Another key question is the cause of the reversible
ectodermal and gastrointestinal mucosal abnormalities
characteristic of CCS. Although numerous factors have
been suggested, such as genetic abnormalities [40], stress
[41], immune dysregulation [5, 34, 35, 42, 43], and low-
turnover cell differentiation [37, 44], no consensus has
emerged, likely owing to the rarity of CCS. In our analysis,
no familial occurrence was verified, one patient improved
only after removal of stress, and another achieved pro-
longed clinical remission with nutrition therapy alone.
Nevertheless, remission in the absence of specific therapies
is difficult to distinguish from spontaneous improvement.
As for immune disorders, only six cases were comorbid
with immunological thyroid disease, one with rheumatoid
arthritis, and 22 were low-titer antinuclear antibodies
positive, inconsistent with an autoimmune cause [42].
There are several reports suggesting the strong association
of CCS with IgG4-related disorders [5, 34], but in this
study no examined serum sample was positive for IgG4,
although the number of samples studied was low (n = 10).
Moreover, no IgG4-positive plasma cells were reported in
biopsy specimens (data not shown). Other proposed theo-
ries such as dysregulation of crypt cell differentiation and
altered intestinal mucin production await experimental
confirmation [14, 37, 44].
The risk of neoplasia remains controversial, with
ongoing questions regarding the carcinogenic potential of
the disease. Among 383 reported cases of CCS in Japan
from 1980 to 2011, 40 patients (54 lesions; 10.2 %) with
coincident gastric cancer and 51 patients (69 lesions) with
coincident colon cancer were identified [7, 9, 22, 45]. In
this study, the prevalence of gastric or colon cancer among
CCS patients was approximately 10–20 %, similar to pre-
vious reports, both significantly higher than the prevalence
of these cancers in the general Japanese population [46]. In
our survey, more than 75 % of gastric cancers were well-
differentiated adenocarcinoma, with 34.6 % of polypoid
lesions diagnosed as tubular adenoma. Furthermore, in the
colon, seven cases of adenoma-bearing carcinomatous foci
were detected, with all early colon cancers detected close
to the adenoma. Although these histopathological findings
are consistent with the adenoma–carcinoma sequence
driving CCS-related malignancy, aberrant crypt maturation
or chronic inflammation in the lamina propria may increase
malignant potential via inflammation-induced mutation [4,
47].
This retrospective study not only describes the largest
number of cases over the longest observation period of all
analogous published studies, it is also the first study
incorporating extensive clinical and endoscopic evalua-
tions, underscoring how endoscopic remission influences
the course of CCS. Nevertheless, these cases were col-
lected exclusively from teaching hospitals in an effort to
obtain the most accurate endoscopic information, possibly
inducing selection bias. Another limitation was that the
334 J Gastroenterol (2016) 51:327–336
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bulky questionnaire, intended to accumulate useful objec-
tive data, seemed sometimes difficult to answer thoroughly,
resulting in the ‘‘inadequate cases.’’ Because of the rarity
of CCS, controlled trials for treatment are extremely dif-
ficult in CCS populations. Further prospective studies are
need to gather further data regarding the effectiveness of
steroid-sparing treatment, such as immunomodulators or
biologics, for the induction of remission for severe disease
[48], and for long-term maintenance.
In conclusion, appropriate medical therapy can alter the
natural history of CCS. Oral corticosteroid therapy
(30–49 mg/day) appeared to be effective for active CCS.
Its benefits, including clinical improvement and polyp
regression, are usually apparent within 12 months. Durable
polyp regression (endoscopic remission) is associated with
a markedly improved prognosis, with decreased cancer
risk. Annual surveillance colonoscopy is recommended to
assess mucosal disease activity and to remove adenomas
and other premalignant mucosal lesions.
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